

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose **ALL** financial relationships they have had in the past **24 months** with ineligible companies. The ACCME *Standards for Integrity and Independence* require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past **24 months** are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of **ALL** financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

NCCN Staff Disclosures

None of the planners for this educational activity have **relevant** financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Congress Planning Committee

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriela S. Hobbs, MD

AbbVie, Inc.: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences, Inc.: Consulting Fee
Incyte Corporation: Grant/Research Support; Scientific Advisor
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Consulting Fee
PharmaEssentia USA Corporation: Consulting Fee
Regeneron Pharmaceuticals: Equity Interest/Stock Options

Shaji K. Kumar, MD*

AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb: Grant/Research Support; Scientific Advisor
CARsgen Therapeutics: Grant/Research Support
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Moderna, Inc.: Consulting Fee
Oricell Therapeutics: Grant/Research Support
Pfizer Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

Bernard L. Marini, PharmD, BCOP*

Servier: Consulting Fee

MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN*

BD: Consulting Fee; Honoraria

Andrew D. Zelenetz, MD, PhD*

AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Scientific Advisor
ADC Therapeutics: Scientific Advisor
Amgen Inc.: Consulting Fee
Arvinas: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Eli Lilly and Company: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support

**Presenting Faculty/Moderator*

Disclosure Information

Faculty Disclosures (continued)

Presenting Faculty

The faculty listed below have **no relevant financial relationships** with ineligible companies to disclose.

Naveen Pemmaraju, MD

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.

Jeremy S. Abramson, MD, MMSc

AstraZeneca Pharmaceuticals LP: Honoraria
BeiGene: Consulting Fee; Honoraria
Bristol Myers Squibb: Consulting Fee; Grant/Research Support; Honoraria
Cellestar: Consulting Fee
Cellestis: Grant/Research Support
Eli Lilly and Company: Consulting Fee
Epizyme, Inc.: Consulting Fee
Foresight Diagnostics: Consulting Fee
Genentech, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Incyte Corporation: Honoraria
Interius BioTherapeutics, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Regeneron Pharmaceuticals: Grant/Research Support
Roche Laboratories, Inc.: Consulting Fee
SeaGen: Consulting Fee; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

Philippe Armand, MD, PhD

Adaptive Biotechnologies: Grant/Research Support
ADC Therapeutics: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
ATB Therapeutics: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Grant/Research Support; Scientific Advisor
Enterome: Consulting Fee
Foresight Diagnostics: Scientific Advisor
Genentech, Inc.: Grant/Research Support; Scientific Advisor
GenMab: Scientific Advisor
IGM Biosciences Grant/Research Support
Kite Pharma: Grant/Research Support
Merck & Co., Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Scientific Advisor
Roche Laboratories, Inc.: Scientific Advisor
Tessa Therapeutics: Officer, Director or any other fiduciary role
Xencor: Consulting Fee; Scientific Advisor

Muhammed Baljevic, MD

BMS/Celgene: Scientific Advisor
Cardinal Health Specialty Solutions: Honoraria
CurioScience: Honoraria
Janssen Research & Development, LLC: Scientific Advisor
Parexel International (MA) Corporation: Honoraria
Pfizer Inc.: Consulting Fee
Sanofi-Genzyme: Scientific Advisor

Faculty Disclosures (continued)

Presenting Faculty

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Ellin Berman, MD

Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support

Danielle M. Brander, MD

AbbVie, Inc.: Consulting Fee; Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Catapult Therapeutics: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Juno Therapeutics, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Newave Inc.: Grant/Research Support
Nurix Therapeutics, Inc.: Grant/Research Support
Pharmacyclics: Consulting Fee; Grant/Research Support

Andrew M. Brunner, MD

Agios, Inc.: Consulting Fee
Bristol Myers Squibb/Celgene: Consulting Fee
Geron: Consulting Fee
i-Mab Biopharma: Consulting Fee
Keros Therapeutics: Consulting Fee
Lava Therapeutics: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Rigel Pharmaceuticals: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Julie E. Chang, MD

AbbVie, Inc.: Consulting Fee
BeiGene: Scientific Advisor
Celgene Corporation: Grant/Research Support
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Ono Pharmaceutical Co., Ltd.: Scientific Advisor

Jennifer Crombie, MD

AbbVie, Inc.: Consulting Fee; Grant/Research Support
ADC Therapeutics: Consulting Fee
Bayer HealthCare: Grant/Research Support
Genentech/Roche: Consulting Fee
GenMab: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Consulting Fee
SeaGen: Consulting Fee

Christopher R. D'Angelo, MD

AbbVie, Inc.: Consulting Fee
BeiGene: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Grant/Research Support
Curis, Inc.: Consulting Fee; Grant/Research Support
Fate Therapeutics: Grant/Research Support
GenMab: Consulting Fee; Grant/Research Support
Ono Pharma: Consulting Fee

Faculty Disclosures (continued)

Presenting Faculty

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Aaron T. Gerds, MD, MS

AbbVie, Inc.: Consulting Fee
Agiros, Inc.: Consulting Fee
Bristol Myers Squibb: Consulting Fee
Disc Medicine: Consulting Fee
GSK: Consulting Fee
PharmaEssentia: Consulting Fee
Rain Oncology: Consulting Fee

Jens Hillengass, MD, PhD

Amgen Inc.: Honoraria
Angitia Biopharmaceuticals: Scientific Advisor
Axess Network: Scientific Advisor
BeiGene: Honoraria
Curio Science: Honoraria
Janssen Pharmaceutica Products, LP: Scientific Advisor
Prothena: Scientific Advisor
Regeneron Pharmaceuticals: Scientific Advisor
Sebia Inc.: Scientific Advisor

Matthias Holdhoff, MD, PhD

Advarra, Inc.: Honoraria
AnHeart Therapeutics: Scientific Advisor
Bayer HealthCare: Scientific Advisor
Novartis Pharmaceuticals Corporation: Honoraria; Scientific Advisor
PAREXEL International Corporation: Honoraria
Servier: Scientific Advisor

Boyu Hu, MD

AbbVie, Inc.: Consulting Fee
ADC Therapeutics: Consulting Fee
Artiva Biotherapeutics: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Caribou Biosciences: Consulting Fee; Grant/Research Support
Celgene Corporation: Grant/Research Support
CRISPR Therapeutics: Grant/Research Support
Eli Lilly and Company: Consulting Fee
Genentech, Inc.: Grant/Research Support
GenMab: Consulting Fee
ImmPACT Bio: Consulting Fee
Kite Pharma: Consulting Fee
MorphoSys AG: Grant/Research Support
Newave: Grant/Research Support
Repare Therapeutics: Grant/Research Support
Regeneron Pharmaceuticals: Consulting Fee
SeaGen: Consulting Fee

Iris Isufi, MD

Bristol Myers Squibb: Consulting Fee
Caribou: Consulting Fee
Incyte Corporation: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Kite Pharma: Product/Speakers Bureau

Faculty Disclosures (continued)

Presenting Faculty

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Patricia A. Mangan, MSN, RN, APRN-BC, CRNP

Bristol Myers Squibb: Honoraria
Janssen Pharmaceutica Products, LP: Honoraria
Karyopharm Therapeutics: Honoraria

Alice S. Mims, MD, MS

AbbVie, Inc.: Consulting Fee
Bristol Myers Squibb: Consulting Fee
Daiichi- Sankyo Co.: Scientific Advisor
Jazz Pharmaceuticals Inc.: Consulting Fee
Foghorn Therapeutics: Scientific Advisor
Notable Labs: Scientific Advisor
Rigel Therapeutics: Consulting Fee
Ryvü Therapeutics: Consulting Fee
Treadwell Therapeutics: Consulting Fee

Kathy Mooney, MSN, RN, ACNS-BC, BMTCN, OCN

Johnson & Johnson: Consulting Fee
Kite Pharma: Product/Speakers Bureau

Jae H. Park, MD

Adaptive Biotechnologies: Consulting Fee
Affymune: Consulting Fee
Allogene: Consulting Fee
Amgen Inc.: Consulting Fee
Artiva Biotherapeutics: Consulting Fee
Autolus: Consulting Fee
Bright Pharmaceuticals Services, Inc.: Consulting Fee
Curocel: Consulting Fee; Equity Interest/Stock Options
In8bio: Consulting Fee
Kite Pharma: Consulting Fee
Minerva Biotechnologies: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Servier: Consulting Fee
Sobi: Consulting Fee
Synthekine: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Kiah Purcell, MSN, AGPCNP-BC

Janssen Pharmaceutica Products, LP: Consulting Fee

David A. Russler-Germain, MD, PhD

AstraZeneca Pharmaceuticals LP: Consulting Fee
Cartography Biosciences: Consulting Fee
Regeneron Pharmaceuticals: Consulting Fee

Faculty Disclosures (continued)

Presenting Faculty

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Bianca D. Santomasso, MD, PhD

Bristol Myers Squibb: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
In8bio: Scientific Advisor
Incyte Corporation: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Legend Biotech: Consulting Fee

Stephen D. Smith, MD

AbbVie, Inc.: Consulting Fee
ADC Therapeutics: Consulting Fee; Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Bayer HealthCare: Grant/Research Support
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
DeNovo Biopharma LLC: Grant/Research Support
Enterome: Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support
Incyte Corporation: Consulting Fee; Grant/Research Support
Karyopharm Therapeutics: Consulting Fee
Kite Pharma: Consulting Fee
Kymera Therapeutics: Grant/Research Support
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Grant/Research Support
Nanjing Pharmaceuticals: Grant/Research Support
Numab Therapeutics: Consulting Fee
Viracta Therapeutics: Grant/Research Support

Jacob D. Soumerai, MD

Adaptive Biotechnologies: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Grant/Research Support
BostonGene: Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Genentech/Roche: Consulting Fee; Grant/Research Support
GSK: Grant/Research Support
LOXO@Lilly: Consulting Fee
Moderna, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
TG Therapeutics: Grant/Research Support

Elizabeth M. Umbro, MSN, CRNP

AbbVie, Inc.: Consulting Fee
CTI BioPharma Corp.: Consulting Fee

Tarun Wasil, MD

AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Eli Lilly and Company: Consulting Fee
GSK: Consulting Fee
Pfizer Inc.: Consulting Fee